OraSure Technologies, Inc. said consolidated net revenues increased 14% to $30.9 million for the three months ended September 30, 2026, while operating loss narrowed to $13.0 million from $16.1 million.
OSUR · Orasure Technologies Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Orashure Technologies reported third-quarter revenue of $30.9 million, up 14% year-over-year, and now expects operating cash-flow break-even in the second half of 2027 instead of entering 2027.
OraSure Technologies reported net revenues of $30.9 million, up 14%, and an operating loss of $13.0 million versus $16.1 million. In June 2026, it received FDA 510(k) clearance for its Colli-Pee™•Dx Urine Collection Kit.
OraSure Technologies announced third-quarter 2026 revenue of $30.9 million, up 14% year-over-year, with GAAP gross margin of 45.2% and GAAP net loss of $13.1 million. It guided Q4 2026 revenue from $30.0 million to $32.0 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. Q3 delivered 14% revenue growth, meaningful gross-margin expansion, lower operating spend, strong segment growth, and initial orders from two product launches, while management expects revenue growth to accelerate in 2027. The company remained loss-making and cash-consuming, and management expects cash-flow-from-operations break-even in the second half of 2027.
- + Q3 revenue grew 14% year-over-year and approximately 1% sequentially to $30.9 million.
- + GAAP gross margin expanded 173 basis points to 45.2%, while non-GAAP gross margin increased to 45.9%.
- + Operating spend improved materially on a sequential basis.
- + Diagnostics revenue increased 16% to $16.8 million and Sample Management Solutions revenue increased 21% to $12.5 million.
- + The Colli-Pee Dx and OraQuick Ebola 2.0 launches generated initial orders in Q3.
- + Management expects full-year revenue growth to accelerate in 2027 from 2026.
- − Q3 operating cash flow was negative $10.9 million.
- − Cash-flow-from-operations break-even was originally planned for entering 2027 but is now expected in the second half of 2027.
- − The CT&G test remained in the FDA pre-submission process following its August submission withdrawal.
- − GAAP net loss was $13.1 million in Q3 2026 versus $13.7 million in Q3 2025.
- − Q4 gross margin was expected to be similar to or slightly below Q3.
- − Adoption occurs through African-led, country-specific pathways for evaluation, registration, procurement, and deployment, and these new processes are taking time even during an urgent outbreak.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Core revenues | 30.9M | the third quarter of 2026 | — |
| Diagnostics revenues | 16.8M | the third quarter of 2026 | — |
| Non-GAAP Cost of Goods Sold non-GAAP | 49.62M | nine months ended September 30, 2026 | — |
| Non-GAAP Gross Margin non-GAAP | 44.5% | nine months ended September 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | 14.19M | the third quarter of 2026 | — |
| Non-GAAP Loss Per Share non-GAAP | -$0.59 | nine months ended September 30, 2026 | — |
| Non-GAAP Net Loss non-GAAP | -40.89M | nine months ended September 30, 2026 | — |
| Non-GAAP operating loss non-GAAP | -43.99M | the nine months ended September 30, 2026 | — |
| Non-GAAP operating margin non-GAAP | -33% | the third quarter of 2026 | — |
| Sample Management Solutions revenues | 12.5M | the third quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OSUR
this stock
Orasure Technologies Inc
|
$247.88M | +48.3% | +30.3% | — | 3.8% |
|
ISRG
Intuitive Surgical Inc
|
$145.92B | -25.7% | +20.5% | 51.0 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.86B | — | +8.2% | 95.6 | 3.0% |
|
MDLN
Medline Inc.
|
$51.51B | -6.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$36.15B | -4.5% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 23
OraSure Technologies, Inc. said consolidated net revenues increased 14% to $30.9 million for the three months ended September 30, 2026, while operating loss narrowed to $13.0 million from $16.1 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OSUR | +0.8% | -7.0% | -16.5% | -8.9% | +48.4% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +4.7% | -1.4% | -13.0% | -5.5% | +41.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.